NEW YORK (TheStreet) -- Medtronic Inc. (MDT - Get Report) stock has received several upgrades from analyst firms Tuesday, following its proposed cash-and-stock deal to purchase Covidien (COV) a day earlier.
Morgan Stanley upgraded to "overweight" from "equal-weight" with a $73 price target, noting the acquisition will drive big returns.
RBC Capital upgraded to "outperform" from "sector perform" with a $73 price target. Analysts said the deal makes both financial and strategic sense.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts